Results 141 to 150 of about 99,639 (312)

SIC1 is ubiquitinated in vitro by a pathway that requires CDC4, CDC34, and cyclin/CDK activities [PDF]

open access: yes, 1997
Traversal from G1 to S-phase in cycling cells of budding yeast is dependent on the destruction of the S-phase cyclin/CDK inhibitor SIC1. Genetic data suggest that SIC1 proteolysis is mediated by the ubiquitin pathway and requires the action of CDC34 ...
Deshaies, Raymond J.   +2 more
core  

Activity‐restoring mutations in the histamine H3 receptor increase constitutive activity and reduce structural stability

open access: yesProtein Science, Volume 35, Issue 1, January 2026.
Abstract The histamine H3 receptor (H3R) is a class A G protein‐coupled receptor (GPCR) that regulates neurotransmitter release in the central nervous system. Although structures of H3R in both inactive and active states have been elucidated, the functional roles of specific residues remain unclear.
Ami Nakajima   +6 more
wiley   +1 more source

Cell cycle regulation of a Xenopus Wee1-like kinase [PDF]

open access: yes, 1995
Using a polymerase chain reaction-based strategy, we have isolated a gene encoding a Wee1-like kinase from Xenopus eggs. The recombinant Xenopus Wee1 protein efficiently phosphorylates Cdc2 exclusively on Tyr- 15 in a cyclin-dependent manner.
Coleman, Thomas R.   +2 more
core  

Physiologically‐Based Pharmacokinetic Modeling of the PARP Inhibitor Niraparib

open access: yesCPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 1, January 2026.
ABSTRACT A physiologically‐based pharmacokinetic (PBPK) model of niraparib and its primary metabolite using a relevant virtual cancer population is reported here. A series of in vitro experiments using liver S9, microsomes, and hepatocytes with various inhibitors and recombinant supersomes demonstrated that niraparib is specifically metabolized by ...
Gareth J. Lewis   +3 more
wiley   +1 more source

High-levelexpression of functional recombinant human coagulation factor VII in insect cells [PDF]

open access: yes
: Recombinant coagulation factor VII (FVII) is used as a potential therapeutic intervention in hemophilia patients who produce antibodies against the coagulation factors.
AD Shapiro   +30 more
core   +1 more source

Preparation and Characterization of Niosomes for Bacteriophage Delivery

open access: yesSmall Science, Volume 6, Issue 1, January 2026.
Incorporation of stearylamine into the niosome bilayer imparts a positive surface charge that promotes electrostatic interactions with negatively charged bacteriophages. This modification facilitates efficient phage encapsulation while preserving phage activity, demonstrating a simple strategy to enhance niosome‐based delivery systems for phage therapy.
Ashley Hannah George   +7 more
wiley   +1 more source

Global Screening of Antiviral Genes that Suppress Baculovirus Transgene Expression in Mammalian Cells

open access: yesMolecular Therapy: Methods & Clinical Development, 2017
Although baculovirus has been used as a safe and convenient gene delivery vector in mammalian cells, baculovirus-mediated transgene expression is less effective in various mammalian cell lines.
Chia-Hung Wang   +4 more
doaj   +1 more source

Do stylet‐borne aphid‐transmitted viruses share the same binding sites?

open access: yesAnnals of Applied Biology, Volume 188, Issue 1, Page 87-101, January 2026.
Here, we tested if different stylet‐borne aphid‐transmitted viruses can compete for the same binding sites within the aphid stylets. We conducted sequential transmission assays of a potyvirus (ZYMV) followed by a cucumovirus (CMV) using Aphis gossypii as a vector and melon and pepper as test plants.
Rocío Galán‐Cubero   +11 more
wiley   +1 more source

Safety and Efficacy of Plant‐Produced Trivalent Virus‐Like Particle Vaccine Candidate Against Bluetongue Disease

open access: yesPlant Biotechnology Journal, Volume 24, Issue 1, Page 273-283, January 2026.
ABSTRACT Bluetongue (BT) is a non‐contagious, insect‐transmitted disease of wild and domestic ruminants caused by bluetongue virus (BTV). Effective control of BT disease relies on vaccination against prevalent or seasonal serotypes using live attenuated or inactivated vaccines.
Tendai A. M. Mlingo   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy